Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MR-Guided Hypofractionated Adaptive Radiation Therapy With Chemotherapy and Durvalumab for NSCLC
NCT03916419Phase 2Completed
- Sponsor
- Washington University School of Medicine
- Start
- Jun 2019
- Primary completion
- Sep 2025
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label trial of durvalumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Washington University School of Medicine. Primary endpoints: Number of Participants With Dose Limiting Toxicities at 6 months, Local Control Rate at 731 days and 1 more. Started Jun 2019; status: completed.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03916419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03916419.